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Pathophysiology 
APNs must recognize symptoms of MG 
early to begin proper treatment.  As seen in 
this case study, symptoms of MG are 
variable making MG difficult to diagnose.  
The patient developed ocular symptoms 
rapidly without fluctuations in muscle 
weakness.  Typically MG is gradual with 
periods of exacerbation and remission.  
Patients generally experience increased 
muscle fatigue in the evening, unlike the 
patient in the case study.  The patient 
stated he experienced heightened muscle 
fatigue often in the morning and at 
different times throughout the day.  The 
patient’s MG was believed to be triggered 
by a virus causing the body to produce 
anti-AChR antibodies that began blocking 
receptors in the extraocular muscles.  The 
patient’s case is also rare in that clinical 
presentation was limited to ocular 
symptoms and did not progress to other 
skeletal muscles.  According to Koch et al. 
(2013), only 10% to 40% of symptoms are 
limited to extraocular muscles (EOMs).  
Because the patient sought medical 
assistance rapidly and physicians were 
able to confirm a diagnosis of MG, the 
patient was treated properly and overall 
outcomes were improved.  It is unknown 
whether symptoms would have progressed 
beyond the EOMs if diagnosis and 
treatment were delayed.  
     Myasthenia gravis (MG) is a rare, 
chronic autoimmune disease that affects 
the neurotransmitter acetylcholine and the 
acetylcholine receptors at the 
neuromuscular junction (Mestecky, 2013).  
MG causes fluctuating skeletal muscle 
weakness and fatigue.  According to the 
Myasthenia Gravis Foundation of America 
(MGFA) (2010), 20 per 100,000 patients 
are diagnosed with MG, although 
researchers believe several more patients 
are misdiagnosed or missed entirely.   
       Several neurological disorders have 
similar clinical presentations to MG making 
it difficult for inexperienced practitioners 
to identify and properly diagnose patients.  
Patients are often misdiagnosed and 
delayed proper treatment for one to two 
years after initial presentation of 
symptoms (Koch, Steele, & Koch, 2013).  
Remissions and exacerbations make MG 
difficult for practitioners to diagnose 
(Weeks, 2012).   
     Other possible differential diagnoses 
include:  
• Guillian Barré 
• Bell’s palsy 
• Multiple Sclerosis 
• Amyotrophic lateral sclerosis 
• Polymyositis  
• Stroke 
     As an Advanced Practice Nurse (APN), it 
is important to understand the variable 
clinical presentations that can occur with 
this disease.  The purpose of this 
presentation is to discuss an individual 
case study and review the pathophysiology 
of MG in order to assist the APN in 
recognizing symptoms early.   
 
 
      
 
     A 59-year-old Caucasian male was seen 
by his primary care provider (PCP) with 
complaints of blurred vision and  increased 
difficulty raising his eyelids.  Upon further 
evaluation, the PCP learned the patient had 
recently returned home from a one week 
long trip to Utah.  While in Utah, the patient 
stated he developed a bad cold with 
symptoms of extremely sensitive, watery 
eyes and severe headaches.  Symptoms 
progressed throughout the week with 
continued complaints of double vision and 
weakness in raising bilateral eyelids.  
Weakness was noted in both eyes, although 
the patient stated his right eye was worse 
than the left eye.  Upon returning home, the 
patient was first seen by his optometrist who 
recommended further evaluation by his 
primary care provider (PCP).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     MG is an autoimmune disease caused 
by autoantibodies that target skeletal 
muscles (Cufi et al., 2012).  Researchers 
believe a virus or bacteria is responsible 
for triggering the body’s autoimmune 
response (Weeks, 2012).  Once the 
immune system is triggered, activated B 
cells, or plasma cells, begin producing 
immunoglobulin G (IgG).  Synthesis of 
anti-AChR antibodies require activated 
CD4+ T cells to interact with and 
stimulate B cells (Cufi et al., 2012).  The 
thymus gland, suspected in developing 
autoantibodies that block receptor sites 
for acetylcholine (ACh), stores T cells and 
is a common target organ for infectious 
diseases. (Cufi et al., 2012).   
     ACh is a neurotransmitter responsible 
for producing voluntary muscle 
contraction.  Voluntary muscles are 
controlled by nerve impulses sent from 
the brain to motor neurons that stimulate 
one or more muscle cells within the 
neuromuscular junction (NMJ) (McCance, 
et al., 2014).   
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Implications 
     As seen in this case study, MG can have 
presentations similar to other 
neurological diseases.  Because MG is 
relatively rare with variable clinical 
presentations, it is important for the APN 
to understand the subtypes and 
characteristics.  To avoid misdiagnosis, 
APNs should consider MG when patients 
report fluctuating muscle weakness 
(Abbott, 2010).  Understanding variations 
of MG can assist the APN in confirming a 
diagnosis and avoid delays in treatment 
(Koch et al., 2013).  A thorough review of 
symptoms along with a complete physical 
and neurological examination is vital to 
diagnose MG.  MG should also be included 
in the differential diagnosis for any 
patient who reports fluctuating muscle 
weakness and complaints of ophthalmic, 
neurologic, or gastrointestinal issues 
(Abbott, 2010). Although there is 
currently no cure for MG, recognizing 
symptoms early can improve patient 
outcomes.  Early diagnosis and treatment 
can improve patient outcomes and 
decrease disease progression.  With 
proper treatment, patients with MG can 
lead relatively normal lives.     
Conclusion 
      
     NMJs are formed as axons divide and 
enter skeletal muscles (Weeks, 2012).  
When stimulated, ACh is released from the 
axons (Weeks, 2012).  Voluntary skeletal 
muscle contractions occurs from the 
binding of ACh to the nicotinic 
acetylcholine receptors (AChR) (Mestecky, 
2013).  The NMJ also consists of a synaptic 
cleft which contains acetylcholinesterase 
(AChE), an enzyme responsible to 
hydrolyze ACh and terminate signal 
transmission (Trouth, Dabi, Solieman, 
Kurukumbi, & Kalyanam, 2012).  
     Anti-AChR antibodies affect 
neuromuscular transmission through 
complement binding and activation, 
antigenic modulation, or complete 
blockage of the AChR (Cufi et al., 2012).   
This blockage causes a defect in nerve 
impulse transmission at the NMJ (McCance 
et al., 2014).  Over time, functional loss of 
AChRs occurs and affected muscles 
become inadequately stimulated resulting 
in weakness and fatigability (Mestecky, 
2013). Antibodies destroy receptor sites 
faster than the body can replace them, 
reducing receptor sites by approximately 
80% (MGFA, 2010).   
     Generally patients over 50 years of age 
have normal or atrophic thymus glands 
(Koch et al., 2013).  Approximately 70% of 
patients with MG continue to produce 
antibodies as a result of thymus 
hyperplasia or tumors, called thymomas 
(Weeks, 2012).  
     
 
      
Clinical Features 
 
 
     Thymomas are usually benign, thymic 
epithelial tumors.  Approximately 30-50% 
of patients with thymomas develop MG 
(Priola & Priola, 2014).  Thymectomy is 
generally recommended for patients with 
thymoma and reduces symptoms in 
approximately 70% of patients (Weeks, 
2012).   The patient presented in this case 
study later discovered he did not have a 
thymoma.  Koch et al. (2013) recommend 
all patients with MG have a computed 
tomography or magnetic resonance 
imaging to detect presence of thymomas.   
   In addition to those who produce AChR 
antibodies, two other subtypes of MG exist: 
seronegative-MG and muscle-specific 
tyrosine kinase (MuSK) MG (Mestecky, 
2013).  No antibodies are identified in 
patients with seronegative-MG.  Patients 
with MuSK-MG produce antibodies that 
attack a different protein, the muscle-
specific tyrosine kinase, in the NMJ 
(Mestecky, 2013).   
 
 
Epidemiology 
     The patient was sent for an immediate 
magnetic resonance image (MRI) with 
suspicions of an aneurysm or stroke.   
Results of the MRI were normal.  The 
patient was then referred to a 
neurologist for additional testing. After 
an ophthalmic catheterization to rule out 
blockages and several neurological 
examinations, results were inconclusive.  
A tensilon test was performed to confirm 
suspicions of MG.  Following the positive 
tensilon test, the patient was checked for 
acetylcholine receptor antibodies (AChR-
Abs) which were present in the patient’s 
blood serum.  AChR-Abs are detected in 
approximately 50% of patients with 
ocular MG, although AChR-Abs are 
present in 80-90% of patients with 
generalized MG (Azeem, Law, & Arora, 
2014).  
Case Study Cont’d 
• MG occurs in all races and affects both 
males and females (MGFA, 2010). 
• Asians, compared to other ethnic 
groups, have a slightly more common 
onset of MG at a younger age (Weeks, 
2012).   
• MG can occur at any age although 
most patient affected are over fifty 
years of age (Abbott, 2010).   
• Women are often affected more than 
men during the first five decades, 
where as men are more commonly 
affected between the sixth and eighth 
decade (Koch et al., 2013).  
• Approximately 20,000 to 70,000 
people in the United  States are 
affected by MG (McCance, Huether, 
Brashers, & Rote, 2014).   
• Advances in treatment options such as 
plasmapheresis, immune therapy, and 
thymectomy are believed to have 
increased patient’s longevity (Abbott, 
2010).   
• Although MG is not hereditary, 5% of 
cases show a familial predisposition 
for acquiring the disease (Weeks, 
2012). 
• There are two main clinical categories 
of MG: generalized AChR myasthenia 
and ocular myasthenia.  
• Ocular myasthenia symptoms are 
limited to the eyelids and extraocular 
muscles (Azeem et al., 2014).   
• Generalized AChR myasthenia includes 
generalized symptoms in which 
bulbar, limb, and respiratory muscles 
are affected (Azeem et al., 2014).   
• Patients who experience generalized 
symptoms typically present with 
ocular symptoms first (Weeks, 2012).      
• Fluctuating muscle weakness in 
ocular, bulbar, respiratory, and limb 
muscles is a hallmark sign of MG 
(Khan & Bennett, 2014).   
• Muscle weakness is often less in the 
morning when ACh stores are highest 
(Abbott, 2010).   
• Emotional stress, heat, infections, 
surgery, and hyperthyroidism can 
exacerbate symptoms and cause 
muscle fatigue (Koch et al., 2013).   
• In the majority of patients, initial 
presentations of ptosis and diplopia 
are the primary symptoms (Koch et al., 
2013).   
• Ptosis and diplopia occur from 
extraocular muscle (EOM) weakness.  
• Other common presentations include 
slurred speech, dysphagia, dysarthria 
and limb weakness (MGFA, 2010).   
• Muscle weakness is typically 
exacerbated with prolonged or 
provoked muscle use and improves 
with periods of rest (Abbott, 2010).   
• Detailed review of systems is 
imperative to uncover symptoms 
patients may believe are insignificant, 
such as decreased weakness in the 
evening or after strenuous activities 
(Abbott, 2010). 
• Include muscle strength testing and 
attempt to provoke muscle fatigue by 
asking patients to maintain an upward 
gaze.  Fluctuating muscle strength is 
commonly seen in the ocular and 
oropharyngeal muscles (Abbott, 
2010). 
 
Common Signs and Symptoms 
• Ptosis (most common early sign) 
• Blurred or double vision 
• Slurred speech 
• Difficulty chewing or swallowing 
• Weakness and fatigue in arms and legs 
• Respiratory weakness 
 
 
 
(Muscular Dystrophy Association, 2014) 
(Mestecky, A., 2013, p.111) 
 
   
(Drachman, 2007, p.1) 
